Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients

Clinical and Experimental Nephrology

Volumn 16, Issue 5, 2012, Pages 767-772

  Echida, Yoshihisa ^a   Ogawa, Tetsuya ^b   Otsuka, Kuniaki ^b   Ando, Yoshitaka ^c   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Hidaka Hospital   (Japan)

Author keywords

Cardiovascular disease; Dyslipidemia; Hemodialysis; Mortality; Non HDL cholesterol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; ROC CURVE;

EID: 84868339542     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0615-5     Document Type: Article

References (24)

1. Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2010;14:505-40.
2. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73-7.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis. 2003;39:S1-91.
4. Grundy SM. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med. 2001;161:1379-80.
5. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-9.
6. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Aqharazii M. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis. 2005;45:1067-72.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
9. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363-8.
10. Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis. 2009;203:587-92.
11. Kitamura A, Noda H, Nakamura H, Kiyama M, Okada T, Imano H, et al. Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb. 2011;18:454-63.
12. Nishizawa T, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int. 2003;63(Suppl. 84):S117-20.
13. Shoji T, Masakane I, Watanabe Y, Iseki K. Committee of Renal data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:1112-20.
14. Schreier L, Gonzalez AI, Elbert A, Berg G, Wikibski R. Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients. Metabolism. 2004;53:1013-5.
15. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Aqharazii M. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis. 2005;45:1067-72.
16. Wanner C, Krane V. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients. Am J Kidney Dis. 2003;41(3 Suppl 1):S72-5.
17. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61: 297-304.
18. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45:119-26.
19. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50:791-802.
20. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res. 2004;27:259-66.
21. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48.
22. Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients-clinical implications and therapeutic guidelines. Ther Apher Dial. 2006;10:305-15.
23. Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol. 2006;17:S226-30.
24. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002;61:2240-9.